Bimatoprost / Timolol: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
HAS (France), SMC (Scotland) and TLV (Sweden) recommended or restricted bimatoprost / timolol, while AWMSG (Wales) did not recommend it.
The file has been open for more than a decade: 18.3 years separate the first record, 5 Jul 2006 at HAS (France), from the most recent, 20 Nov 2024 at HAS (France).
TLV (Sweden) changed its position: recommended on 27 Oct 2006, restricted by 27 Dec 2013.
No assessment is on file from PBAC (Australia), PHARMAC (New Zealand), CIPM (Spain) and G-BA (Germany), each among the eight highest-volume agencies here.
HAS (France) was first to assess bimatoprost / timolol, on 5 Jul 2006; AWMSG (Wales) did not open a file until 27 Feb 2014 — a wide spread of 7.6 years between the earliest and latest system to look at it.
The record arrives in waves: 3 separate years each carry two or more decisions, spread across 5 years in total.
Restriction is doing real work here: 2 of 6 decisive outcomes narrowed bimatoprost / timolol to a subgroup rather than accepting or refusing it outright, at SMC (Scotland) and TLV (Sweden).
2 of the 4 agencies here assessed bimatoprost / timolol more than once, HAS (France) most often at 4 entries — repeat review is the norm for this molecule rather than the exception.
Coverage is narrow: only 4 of the 18 agencies here have assessed bimatoprost / timolol.
The full ledger for bimatoprost / timolol reads 3 recommended, 2 other, 2 restricted and 1 not recommended.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| HAS (France) | 20 Nov 2024 | Listing (Transparency Committee) | SMR substantial · ASMR V | source |
| HAS (France) | 9 Mar 2022 | Listing (Transparency Committee) | SMR substantial · ASMR V | source |
| AWMSG (Wales) | 27 Feb 2014 | For the reduction of intraocular pressure in adult patients with open-angle glaucoma or ocular hypertension who are insu… | not endorsed (non-submission) | source |
| TLV (Sweden) | 27 Dec 2013 | Ganfort ingår i högkostnadsskyddet med begränsning | restricted subsidy | source |
| SMC (Scotland) | 7 Oct 2013 | For reduction of intraocular pressure (IOP) in adult patients with open-angle glaucoma or ocular hypertension who are sufficiently responsive to topical beta-blockers or … | accepted (restricted) | source |
3 further decisions for bimatoprost / timolol, across 2 agencies, are not shown here. They link to 3 further source documents.
Related molecules
- latanoprost — same ATC class S01E — Ophthalmologicals
- bimatoprost — same ATC class S01E — Ophthalmologicals
- travoprost — same ATC class S01E — Ophthalmologicals
- dorzolamide / timolol — same ATC class S01E — Ophthalmologicals
- latanoprost / timolol — same ATC class S01E — Ophthalmologicals
- latanoprost / netarsudil — same ATC class S01E — Ophthalmologicals
Coverage: 8 decisions for bimatoprost / timolol from 4 agencies, 2006 to 2024. Data to 7 Sep 2026. ATC class S01E — Ophthalmologicals. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.